Avian influenza vaccine is about to be circulated in the United States

On April 17, the US Food and Drug Administration (FDA) approved the vaccine registration against the H5N1 virus produced by Sanofi Aventis pharmaceutical corporation. This is the first human flu vaccine to be allowed to circulate in the United States.

According to the FDA, the vaccine will not be used immediately in the commercial field and will only be used if the H5N1 virus has mutated and turned into a virus easily transmitted from person to person to form a virus. pandemic. With the permission to register above, the US government has begun implementing vaccine reserves to prevent emergency situations that may occur for avian influenza.

(Photo: pbs.org) Accordingly, the US expects to buy and store enough vaccine for 20 million people, including those from emergency intervention agencies and health workers or even for soldiers. before they are deployed overseas. Clinical trials have shown that vaccines against bird flu, indicated in two times, have an immune effect only in 45% of adults who receive the maximum dose.

Meanwhile, seasonal flu vaccines are indicated only once but often protect more than 90% of healthy young people. However, in February last year, FDA advisers identified that the use of the vaccine is still better than not using any vaccine against bird flu.

David Williams, general manager of Sanofi-Aventis in the group's field of vaccines, said Sanofi-Aventis continues to work with US authorities and other partners in promoting research and production of vaccines against avian flu. to prepare the best in case of a pandemic.

GERMANY SCHOOL